Hemab Reports Q3 2026 Financial Results and Clinical Pipeline Updates
Hemab reported its third-quarter 2026 financial results, posting a net loss of $27.3 million, or $0.58 per share. The company's cash and marketable securities stood at $430.2 million as of September 30, 2026, providing a projected cash runway into 2029 to fund ongoing operations and capital expenditures. On the clinical front, Hemab highlighted significant progress across its pipeline. The SOLARA Phase III trial for Glanzmann thrombasthenia is enrolling participants, while Sutacimig demonstrated an 80% mean annualized treated bleed rate reduction in Phase II. Additionally, HMB-002 showed strong proof of mechanism with a 2.5-fold increase in Von Willebrand Factor and Factor VIII, exceeding internal targets.
Topics: biotechnology cash runway clinical trial updates earnings report